Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mustang Bio Inc    MBIO

MUSTANG BIO INC

(MBIO)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
4.64(c) 4.66(c) 4.47(c) 4.31(c) 4.47(c) Last
365 888 43 319 34 413 57 104 106 324 Volume
-17.29% +0.43% -4.08% -3.58% +3.71% Change
More quotes
Financials (USD)
Sales 2018 0,05 M
EBIT 2018 -
Net income 2018 -26,3 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -33,9 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 2 437x
Capi. / Sales2019 0
Capitalization 122 M
More Financials
Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies... 
More about the company
Latest news on MUSTANG BIO INC
2018MUSTANG BIO : Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the ..
AQ
2018MUSTANG BIO : Receives Orphan Drug Designation for MB-102 for the Treatment of B..
AQ
2018Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the..
GL
2018MUSTANG BIO : Announces Presentation of MB-102 Safety and Efficacy Data at AACR ..
AQ
2018Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy ..
GL
2018Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate..
GL
2018MUSTANG BIO : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2018Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corp..
AQ
2018Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corp..
AQ
2018MUSTANG BIO : City of Hope Opens First-of-Its-Kind CAR T Clinical Trial for Pati..
AQ
More news
Analyst Recommendations on MUSTANG BIO INC
More recommendations
Sector news : Bio Therapeutic Drugs
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Bio Therapeutic Drugs
Chart MUSTANG BIO INC
Duration : Period :
Mustang Bio Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MUSTANG BIO INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Manuel Litchman President, Chief Executive Officer & Director
Michael Sean Weiss Chairman
Brian Achenbach Vice President-Finance & Controller
Sadik Kassim Chief Scientific Officer
Knut Niss Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
MUSTANG BIO INC52.04%122
GILEAD SCIENCES6.11%87 436
VERTEX PHARMACEUTICALS12.08%48 081
REGENERON PHARMACEUTICALS9.37%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252